p53 Regulates the Minimal Promoter of the Human Topoisomerase IIα Gene

DNA topoisomerase IIalpha is an essential enzyme for chromosome segregation during mitosis. Consistent with a cell division-specific role, the expression of the topoisomerase IIalpha gene is strongly influenced by the proliferation status of cells. The p53 protein is one of the most important regulators of cell cycle progression in mammals, with an apparent dual role in the induction of cell cycle arrest following cytotoxic insults and in the regulation of the apoptotic cell death pathway. We have analysed whether p53 plays a role in regulating expression of the human topoisomerase IIalpha gene. We show that wild-type, but not mutant, p53 is able to decrease substantially the activity of the full length topoisomerase IIalpha gene promoter. Using a series of constructs comprising various deleted or mutated versions of the promoter lacking critical cis-acting elements, we show that this p53-specific regulation of the topoisomerase IIalpha promoter is independent of all characterised transcription factor binding sites and is directed at the minimal gene promoter. We conclude that expression of wild-type p53 induces downregulation of the human topoisomerase IIalpha promoter by acting on the basal transcription machinery. These findings implicate topoisomerase II as one of the downstream targets for p53-dependent regulation of cell cycle progression in human cells.

[1]  A. Harris,et al.  Regulation of the Human Topoisomerase IIα Gene Promoter in Confluence-arrested Cells* , 1996, The Journal of Biological Chemistry.

[2]  C. Hunt,et al.  The cell cycle-coupled expression of topoisomerase IIalpha during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation , 1996, Molecular and cellular biology.

[3]  X. Liu,et al.  Reversal of in vitro p53 squelching by both TFIIB and TFIID , 1995, Molecular and cellular biology.

[4]  S. Ng,et al.  Molecular Cloning and Characterization of the Promoter for the Chinese Hamster DNA Topoisomerase IIα Gene (*) , 1995, The Journal of Biological Chemistry.

[5]  J. Rayner,et al.  p53 represses SV40 transcription by preventing formation of transcription complexes. , 1995, Oncogene.

[6]  Y. Hirano,et al.  A human temperature-sensitive p53 mutant p53Val-138: modulation of the cell cycle, viability and expression of p53-responsive genes. , 1995, Oncogene.

[7]  H. Kreipe,et al.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. , 1995, The American journal of pathology.

[8]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[9]  S. Friend,et al.  Characterization of human Gadd45, a p53-regulated protein. , 1994, The Journal of biological chemistry.

[10]  P. O'Connor,et al.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.

[11]  I. Hickson,et al.  Structure and function of type II DNA topoisomerases. , 1994, The Biochemical journal.

[12]  P. Nurse,et al.  Premature chromatin condensation upon accumulation of NIMA. , 1994, The EMBO journal.

[13]  B. Ebert,et al.  Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Holm.  Coming undone: How to untangle a chromosome , 1994, Cell.

[15]  F. Vikhanskaya,et al.  Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. , 1994, Nucleic acids research.

[16]  C. Turck,et al.  Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit , 1993, Nature.

[17]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[18]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[19]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[20]  J. Wang,et al.  Transcription and DNA supercoiling. , 1993, Current opinion in genetics & development.

[21]  J. Sng,et al.  Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. , 1993, Biochimica et biophysica acta.

[22]  S. N. Agoff,et al.  Regulation of the human hsp70 promoter by p53. , 1993, Science.

[23]  W. T. Beck,et al.  Drug resistance associated with altered DNA topoisomerase II. , 1993, Advances in enzyme regulation.

[24]  D. Lane,et al.  High levels of p53 protein in UV-irradiated normal human skin. , 1993, Oncogene.

[25]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[26]  A. Harris,et al.  Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. , 1992, Nucleic acids research.

[27]  I. Hickson,et al.  Cloning and characterization of the 5'-flanking region of the human topoisomerase II alpha gene. , 1992, The Journal of biological chemistry.

[28]  H. Westphal,et al.  Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. , 1992, Cancer research.

[29]  P. Friedman,et al.  Wild-type p53 activates transcription in vitro , 1992, Nature.

[30]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression , 1992 .

[31]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[32]  R. W. Jones,et al.  Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Yaniv,et al.  Wild-type p53 can down-modulate the activity of various promoters. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  U. Santhanam,et al.  Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Vogelstein,et al.  Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication , 1991, Cell.

[36]  N. Osheroff,et al.  Catalytic function of DNA topoisomerase II , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[37]  J. Wang,et al.  DNA topoisomerases: why so many? , 1991, The Journal of biological chemistry.

[38]  M. Mattern,et al.  Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[39]  E. Appella,et al.  Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Vogelstein,et al.  p53 functions as a cell cycle control protein in osteosarcomas , 1990, Molecular and cellular biology.

[41]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[42]  T. Chung,et al.  Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. , 1990, Cancer research.

[43]  T. Chung,et al.  Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[44]  G. Hofmann,et al.  Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. , 1989, Biochemistry.

[45]  R. A. Kim,et al.  A subthreshold level of DNA topoisomerases leads to the excision of yeast rDNA as extrachromosomal rings , 1989, Cell.

[46]  A. Kingsman,et al.  Multiple cooperative interactions constrain BPV-1 E2 dependent activation of transcription. , 1989, Nucleic acids research.

[47]  D. Botstein,et al.  DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage , 1989, Molecular and cellular biology.

[48]  P. L. Chen,et al.  Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. , 1988, Science.

[49]  Gerald R. Fink,et al.  Mitotic recombination in the rDNA of S. cerevisiae is suppressed by the combined action of DNA topoisomerases I and II , 1988, Cell.

[50]  J. Wang,et al.  Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Barclay,et al.  A role in transmembrane signaling for the cytoplasmic domain of the CD2 T lymphocyte surface antigen , 1988, Cell.

[52]  T. Uemura,et al.  DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe , 1987, Cell.

[53]  D. Botstein,et al.  DNA topoisomerase II is required at the time of mitosis in yeast , 1985, Cell.

[54]  D. Givol,et al.  Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. , 1985, The EMBO journal.

[55]  Thomas A. Kunkel,et al.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Yaniv,et al.  Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma , 1984, Cell.

[57]  R. Sternglanz,et al.  DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.